Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

MediPharm Labs Q1 2026: revenue falls, adjusted EBITDA positive for first time

MediPharm Labs reported Q1 2026 revenue of CAD 9.0 million (‑16.7% year‑on‑year) but achieved a positive adjusted EBITDA of CAD 0.1 million. Net loss widened to CAD 0.9 million, gross margin was 37%. International revenue accounted for 51% of sales. The company plans annual savings of CAD 1.0 million through restructurings and holds CAD 9.9 million in cash. The stock rose 12.5% in pre-market trading after the results were released. » Mais em de.investing.com
MediPharm Labs beats Q4 revenue forecast by 5.79% and highlights international sales

MediPharm Labs reported Q4 2025 revenue of CAD 14.06 million versus expected CAD 13.29 million (+5.79%) and an EPS of zero, in line with forecasts. The stock rose 7.69% in premarket trading. International medical cannabis sales contributed over 50% of total revenue; the fiscal year recorded revenue growth of 8% and an improved net loss position of CAD 8.3 million. The company emphasizes expansion into foreign markets and the expansion of EU‑GMP capacity for 2026. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, MediPharm Labs já distribuiu € 0,0431 em dividendos. A última distribuição ocorreu em abril de 2022.

Dados financeiros da empresa

No último trimestre, MediPharm Labs registou receitas de € 6,16 mi e um ganho líquido de € 2,47 mil

(EUR)	junho de 2026	YoY
Receitas	6,16 mi	16,34%
Ganho bruto	2,65 mi	27,56%
Ganho líquido	2,47 mil	100,10%
EBITDA	136,35 mil	106,55%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 21 mi
Número de ações	424,86 mi
Máximo/mínimo de 52 semanas	€ 0,0659 - € 0,0355
Dividendos	Não
Beta	0,99
PER (PE Ratio)	-6,47
PEG (PEG Ratio)	-0,10
P/VC (PB Ratio)	0,90
P/V (PS Ratio)	0,77

Perfil da empresa

MediPharm Labs Corp. ist ein pharmazeutisches Unternehmen, das Cannabisöl und -konzentrate in pharmazeutischer Qualität sowie fortschrittliche derivative Produkte in Kanada, Australien, Deutschland und international herstellt und vertreibt. Das Unternehmen formuliert, verarbeitet, verpackt und vertreibt Cannabisextrakte und fortschrittliche Produkte auf Cannabinoidbasis. Das Unternehmen bietet auch GMP-Blumenbeschaffung, Verpackung und Vertriebsdienstleistungen an. MediPharm Labs Corp. wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Barrie, Kanada.